Standard BioTools Inc. (LAB) Fair Value 2026

LAB · Medical Devices ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

5.9 /10

32 fundamental signals · 2 models active

Value Trap Risk

WARN (44/100)

Quick Summary — As of 2026-08-31, Standard BioTools Inc. (LAB) trades at $0.66, versus a $1.23 median fair value across its 2 active models — 86.9% above the current price. QOC: 5.9/10. Value Trap Risk: 44/100 (WARN). 2/13 models active.

Key Facts

Ticker
LAB
Price
$0.66
Quality Score
5.9/10
Value Trap Risk
44/100
Models Active
2/13
Last Updated
Strength: PWERM suggests +119.2% upside with 34% confidence
Risk: Value Trap score of 44 suggests caution despite apparent undervaluation

Is Standard BioTools Inc. (LAB) Undervalued or Overvalued in 2026?

According to CirclFi’s 2-model valuation engine, Standard BioTools Inc. (LAB) appears undervalued as of : the median of 2 independent fair value estimates is $1.23, 86.9% above the current price of $0.66. Estimates range from $1.02 to $1.44. LAB scores 5.9/10 on fundamental quality and 44/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.1% versus its own 13-model consensus, across 3,804 rated companies as of 2026-08-31. LAB’s +86.9% gap is wider than that market norm, and the Medical Devices sector median is -42.6%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Standard BioTools Inc. Stock in 2026? →

What Fair Value Does Each Model Give LAB?

2 Intrinsic Value Models vs. Current Price ($0.66)

Core Models (Unlocked)
Model Fair Value Upside
Asset-Based · High Conviction
 $1.02 +54.6%
Option-Based · Medium Conviction
 $1.44 +119.2%

All Models Active

All 2 models are displayed above.

What Is Standard BioTools Inc. (LAB) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, the weight of evidence tilts decidedly bullish for Standard BioTools Inc.. Trading at $0.66 against an estimated intrinsic value of $1.23, 2 of 2 active models flag meaningful upside of +86.9% at the median. The most optimistic model, PWERM, places fair value at $1.44 (+119.2%), while Dynamic NAV — the most conservative — estimates $1.02 (+54.6%). This +64.6% gap reflects genuine analytical uncertainty about Standard BioTools Inc.'s intrinsic worth.

What Do the Models Say About LAB?

2 of 13 models are currently active for LAB. All 2 active models suggest the stock trades below fair value. Taken together, their median fair value for LAB is $1.23 — the figure CirclFi publishes as this stock's fair value. See which stocks rank higher →

How Does LAB Rank in Medical Devices?

Among 159 Medical Devices stocks, LAB ranks #95 by Quality of Company score. CirclFi's QOC score of 5.9/10 evaluates 32 fundamental signals. A score of 5.9 reflects mixed fundamentals.

See all Most Undervalued Medical Devices Stocks →

As a pharmaceutical industry, Standard BioTools Inc. operates in a sector where revenue per drug is a critical driver of valuation. Investors evaluating LAB should weigh these sector-specific dynamics alongside our model-derived fair values.

Is LAB a Value Trap?

CirclFi's Value Trap algorithm assigns LAB a score of 44/100 (WARN). This is a warning signal. Additional research into recent 10-Q filings is recommended. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

2 of 13 models are active for Standard BioTools Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, Standard BioTools Inc. is rated at 5.9/10. This solid-tier score maintains reasonable quality metrics with some areas for improvement.

The gap between the most bullish and bearish model spans +64.6% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every LAB valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across LAB's 2 active models, average confidence is 45%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Standard BioTools Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Medical Devices Stocks Should You Also Analyze?

11 related Medical Devices stocks with 13-model coverage

BTCYBiotricity, Inc.QOC 6.0XAIRBeyond Air, Inc.QOC 5.8SSIISS Innovations International, Inc.QOC 6.0OWLTOwlet, Inc.QOC 5.8VYCOVycor Medical, Inc.QOC 6.0QDELQuidelOrtho CorporationQOC 5.8PAVMPAVmed Inc.QOC 4.6ESMCEscalon Medical Corp.QOC 8.7ATECAlphatec Holdings, Inc.QOC 6.9IRMDIRADIMED CORPORATIONQOC 9.8PODDInsulet CorporationQOC 9.6

Read investment analysis: BTCY · XAIR · SSII · OWLT · VYCO · QDEL · PAVM · ESMC · ATEC · IRMD · PODD

Which Other Stocks Have a Similar Quality Score to LAB?

7 companies across all industries closest to LAB’s Quality of Company score of 5.9/10.

OKUROnKure Therapeutics, Inc.QOC 5.9TYGOTigo Energy, Inc.QOC 5.9SBGISinclair, Inc.QOC 5.9HAFGHolistic Asset Finance Group Co., Ltd.QOC 5.9EYPTEyePoint, Inc.QOC 5.9RLAYRelay Therapeutics, Inc.QOC 5.9NVDANVIDIA CorporationQOC 10.0

Read investment analysis: OKUR · TYGO · SBGI · HAFG · EYPT · RLAY · NVDA

Where Does LAB Sit in CirclFi's Medical Devices Rankings?

LAB is ranked against every other Medical Devices stock CirclFi covers in each of these screens.

See all Medical Devices stocks ranked →

What Else Do Investors Ask About Standard BioTools Inc.’s Valuation?

What is Standard BioTools Inc.'s intrinsic value in 2026?

CirclFi puts Standard BioTools Inc. (LAB)'s intrinsic value at $1.23 — the median of 2 independent model estimates as of 2026-08-31, ranging from $1.02 to $1.44. The Quality of Company score is 5.9/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is LAB overvalued or undervalued right now?

At $0.66, 2 of 2 active models suggest LAB may be undervalued, while 0 indicate potential overvaluation. The median of all 2 fair value estimates is $1.23, 86.9% above the current price of $0.66 — a consensus view that LAB is undervalued. The assessment depends on which methodology best fits Standard BioTools Inc.'s business model in Medical Devices.

What does a Quality of Company score of 5.9 mean for LAB?

Standard BioTools Inc.'s QOC of 5.9/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on LAB?

CirclFi analyzes LAB with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 2 of 13 are active for this stock. Read the full methodology →

Is LAB a value trap in 2026?

Standard BioTools Inc.'s Value Trap score is 44/100 (WARN). This elevated score suggests the stock may look undervalued but faces deteriorating fundamentals — declining margins, rising debt, or shrinking revenue could make the apparent discount deceptive. Browse our ranked stock lists to compare value-trap scores across industries. Browse stocks by value-trap risk →

Cite this analysis — “According to CirclFi’s 2-model valuation engine, Standard BioTools Inc. (LAB) has a median fair value of $1.23 — 86.9% above the current price of $0.66 — as of 2026-08-31.” Source: circlfi.com/stock/LAB/ · Methodology
Primary sources for this LAB valuation
  • Financial statements: Standard BioTools Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001162194) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for LAB as of ; valuations recomputed .